CEL-SCI Corp. (CVM) Starts Presentation at Annual Marcum MicroCap Conference

CEL-SCI Corp. (NYSE: CVM) is focused on research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system. Its lead investigational therapy, Multikine injection, is currently being studied in a pivotal global Phase 3 clinical trial as a potential first-line treatment for advanced primary head and neck cancer. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine for Rheumatoid. LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1) and the Spanish Flu. For more information, visit the company’s website at www.cel-sci.com